Novuspharma SpA (NOV.MI), a biotechnology company focused on cancer, announced results from a preclinical study with BBR 2778 in a chronic model of multiple sclerosis.
The results were presented by Dr. Guido Cavaletti of the Bicocca University of Milan, together with colleagues and Novuspharma scientists, at the 12th Meeting of the European Neurological Society in Berlin June 22-26, 2002. BBR 2778 is Novuspharma's intercalating agent currently in phase III clinical trials for the treatment of non-Hodgkin lymphoma.
The aim of the preclinical experiments was to examine the effect of BBR 2778 in a chronic, relapsing, experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis by comparing BBR 2778 with mitoxantrone, an anticancer drug approved in U.S. and certain European countries for the treatment of multiple sclerosis.
The data analyzed so far indicate that repeated intravenous administration
of both mitoxantrone and BBR 2778 is effective in preventing disease relapses,
and there are some suggestions of better efficacy of BBR 2778 than mitoxantrone
at the dose level tested. These results are consistent with the effects
seen on the white blood counts: both agents induced a similar and significant
reduction in total white blood cell count in comparison with the control
group. Lymphocytes were reduced accordingly, but more markedly after BBR
2778 administration. The reduction was still evident at the end of the
60-day observation period. Histopathology confirmed previous observations
in addition to showing evidence of BBR 2778's noncardiotoxic properties.
This article was prepared by Drug Week editors from staff and other reports.
© 2002, NewsRx.com